Yajuan Qi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yajuan Qi has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
Jinxiu Chu
School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, 063210, China; Hebei Key Laboratory for Chronic Diseases, School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, 063210, 063200, China; Tangshan Key Laboratory of Basic Research in Medicine Development, North China University of Science and Technology, Tangshan 063210, China
5 shared publicationsJiyuan Guo
5 shared publicationsNaijun Wu
5 shared publicationsDan Li
4 shared publicationsXiaolei Han
Qian'an Hospital of Chinese Medicine, Tangshan, 063210, China
4 shared publicationsXing Li
4 shared publications
Latest Publications
- 24 June 2026
- Published by Elsevier in Life Sciences
- Vol. 402, 124534
Inflammation-mediated diabetes-liver disease cross-organ crosstalk: From molecular mechanisms to precision therapeutic strategies
- 24 June 2026
- Published by Elsevier in Life Sciences
- Vol. 402, 124534
Inflammation-mediated diabetes-liver disease cross-organ crosstalk: From molecular mechanisms to precision therapeutic strategies
- 14 June 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 370, 121996
Linderane, a furanosesquiterpene from Lindera aggregata, targets STAT3 to improve metabolic and inflammatory features of MASLD
- 14 June 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 370, 121996
Linderane, a furanosesquiterpene from Lindera aggregata, targets STAT3 to improve metabolic and inflammatory features of MASLD
- 3 June 2026
- Published by Wiley in Liver International
- Vol. 46 (7) , e70712
AKR1B10 Serves as a Specific Biomarker for the Identification of Hepatocellular Ballooning Degeneration in MASH Patients
Background: Hepatocellular ballooning degeneration distinguishes metabolic dysfunction‐associated steatohepatitis (MASH) from metabolic dysfunction‐associated steatotic liver (MASL), yet specific biomarkers are lacking. Methods: The spatial transcriptomes of liver sections from human MASL and MASH patients and single‐cell data were used to examine hepatocyte ballooning. AKR1B10 and CK8/18 expression in 20 human liver samples were analysed by H&E staining and immunofluorescence. Serum AKR1B10 levels were quantified in 284 patients with various liver aetiologies to assess its differential expression across liver disease types and its diagnostic performance. Results: Spatial and single‐cell transcriptomic analyses revealed significant AKR1B10 enrichment in the ballooned hepatocytes. The proportions of T cells and fibroblasts were significantly greater in ballooning regions than in steatotic regions. Immunostaining confirmed the localization of AKR1B10 in ballooning regions, along with the cytoplasm and cell membrane. This expression pattern was consistent with areas of cytokeratin CK8/18 loss; moreover, their combined application improved the ballooning diagnostic rate and accuracy. Serum AKR1B10 levels were markedly higher in patients with MASH than in individuals with other liver diseases ( p < 0.01) and correlated with ballooning severity ( R = 0.624). Ordinal logistic regression analysis indicated that the serum AKR1B10 level was strongly positively correlated with liver tissue ballooning severity (OR = 1.541 per unit, p = 0.003). The constructed model demonstrated significant discriminatory ability for identifying MASH patients with ballooning (AUC = 0.863). Conclusions: AKR1B10 is a potential diagnostic and therapeutic biomarker for hepatocyte ballooning in MASH patients with strong spatial specificity and clinical value for noninvasive diagnosis, disease stratification, and treatment monitoring.
- 3 June 2026
- Published by Wiley in Liver International
- Vol. 46 (7) , e70712
AKR1B10 Serves as a Specific Biomarker for the Identification of Hepatocellular Ballooning Degeneration in MASH Patients
Background: Hepatocellular ballooning degeneration distinguishes metabolic dysfunction‐associated steatohepatitis (MASH) from metabolic dysfunction‐associated steatotic liver (MASL), yet specific biomarkers are lacking. Methods: The spatial transcriptomes of liver sections from human MASL and MASH patients and single‐cell data were used to examine hepatocyte ballooning. AKR1B10 and CK8/18 expression in 20 human liver samples were analysed by H&E staining and immunofluorescence. Serum AKR1B10 levels were quantified in 284 patients with various liver aetiologies to assess its differential expression across liver disease types and its diagnostic performance. Results: Spatial and single‐cell transcriptomic analyses revealed significant AKR1B10 enrichment in the ballooned hepatocytes. The proportions of T cells and fibroblasts were significantly greater in ballooning regions than in steatotic regions. Immunostaining confirmed the localization of AKR1B10 in ballooning regions, along with the cytoplasm and cell membrane. This expression pattern was consistent with areas of cytokeratin CK8/18 loss; moreover, their combined application improved the ballooning diagnostic rate and accuracy. Serum AKR1B10 levels were markedly higher in patients with MASH than in individuals with other liver diseases ( p < 0.01) and correlated with ballooning severity ( R = 0.624). Ordinal logistic regression analysis indicated that the serum AKR1B10 level was strongly positively correlated with liver tissue ballooning severity (OR = 1.541 per unit, p = 0.003). The constructed model demonstrated significant discriminatory ability for identifying MASH patients with ballooning (AUC = 0.863). Conclusions: AKR1B10 is a potential diagnostic and therapeutic biomarker for hepatocyte ballooning in MASH patients with strong spatial specificity and clinical value for noninvasive diagnosis, disease stratification, and treatment monitoring.
- Open Access
- 10 May 2026
- Published by Wiley in Aging Cell
- Vol. 25 (5) , e70541
Exosome‐Delivered eNAMPT From Exercise Activates SIRT1 to Counteract Age‐Related Hepatic Steatosis and Fibrosis
Aging is a major independent risk factor for the development and progression of metabolic dysfunction‐associated steatotic liver disease (MASLD); however, effective therapeutic strategies for this population remain limited. Here, we established a model of aging‐associated MASLD by subjecting aged mice to a long‐term high‐fat diet (HFD), which recapitulated key disease features including progressive hepatic steatosis, inflammation, insulin resistance, and fibrosis. A 6‐week exercise intervention markedly ameliorated these pathologies by restoring insulin sensitivity and suppressing TGF‐β/Smad‐mediated fibrotic signaling. We identified exercise‐derived exosomes (Exercise‐Exos) as primary mediators of these benefits. Western blot analysis revealed that extracellular nicotinamide phosphoribosyltransferase (eNAMPT) was markedly enriched in Exercise‐Exos compared to those from sedentary controls. Delivery of exosomal eNAMPT activated the hepatic SIRT1‐autophagy axis, restored autophagic flux, and inhibited epithelial‐mesenchymal transition (EMT). These effects were demonstrated by an increased LC3‐II/LC3‐I ratio, reduced p62 accumulation, downregulation of mesenchymal markers (α‐SMA, Vimentin), and upregulation of the epithelial marker E ‐cadherin. Furthermore, Exercise‐Exos treatment significantly reduced collagen deposition. Critically, all protective effects were abolished upon pharmacological inhibition of SIRT1 with EX‐527, establishing the necessity of the eNAMPT‐NAD + ‐SIRT1 cascade. Collectively, our results elucidate a novel exosome‐mediated pathway through which exercise mitigates age‐related liver disease, positioning exosomal eNAMPT as a promising therapeutic agent and exercise mimetic for MASLD.
- 10 May 2026
- Published by Wiley in Aging Cell
- Vol. 25 (5) , e70541
Open AccessExosome‐Delivered eNAMPT From Exercise Activates SIRT1 to Counteract Age‐Related Hepatic Steatosis and Fibrosis
Aging is a major independent risk factor for the development and progression of metabolic dysfunction‐associated steatotic liver disease (MASLD); however, effective therapeutic strategies for this population remain limited. Here, we established a model of aging‐associated MASLD by subjecting aged mice to a long‐term high‐fat diet (HFD), which recapitulated key disease features including progressive hepatic steatosis, inflammation, insulin resistance, and fibrosis. A 6‐week exercise intervention markedly ameliorated these pathologies by restoring insulin sensitivity and suppressing TGF‐β/Smad‐mediated fibrotic signaling. We identified exercise‐derived exosomes (Exercise‐Exos) as primary mediators of these benefits. Western blot analysis revealed that extracellular nicotinamide phosphoribosyltransferase (eNAMPT) was markedly enriched in Exercise‐Exos compared to those from sedentary controls. Delivery of exosomal eNAMPT activated the hepatic SIRT1‐autophagy axis, restored autophagic flux, and inhibited epithelial‐mesenchymal transition (EMT). These effects were demonstrated by an increased LC3‐II/LC3‐I ratio, reduced p62 accumulation, downregulation of mesenchymal markers (α‐SMA, Vimentin), and upregulation of the epithelial marker E ‐cadherin. Furthermore, Exercise‐Exos treatment significantly reduced collagen deposition. Critically, all protective effects were abolished upon pharmacological inhibition of SIRT1 with EX‐527, establishing the necessity of the eNAMPT‐NAD + ‐SIRT1 cascade. Collectively, our results elucidate a novel exosome‐mediated pathway through which exercise mitigates age‐related liver disease, positioning exosomal eNAMPT as a promising therapeutic agent and exercise mimetic for MASLD.
- Open Access
- 23 April 2026
- Published by Elsevier in SSRN Electronic Journal
Linderane, a furanosesquiterpene from Lindera aggregata, targets STAT3 to improve metabolic and inflammatory features of MASLD
Background:Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major global health burden, characterized by insulin resistance, hepatic steatosis, and chronic inflammation. Effective pharmacological treatments remain limited. Linderane (LDR), a furanosesquiterpene isolated from Lindera aggregata, exhibits immunometabolic regulatory activity; however, its role in MASLD has not been fully elucidated.Purpose:To evaluate the therapeutic potential of LDR in MASLD and explore its mechanisms, with a focus on STAT3-mediated immunometabolic pathways.Methods:MASLD was induced in C57BL/6J mice via high-fat diet (HFD) feeding. LDR was administered orally, and metabolic, inflammatory, and histological parameters were assessed. Mechanistic studies were performed in primary hepatocytes and macrophages using Western blotting, RT-qPCR, immunofluorescence, transcriptomics, and cellular thermal shift assays (CETSA).Results:LDR significantly improved fasting and postprandial glucose levels, enhanced insulin sensitivity, and restored GLUT2/GLUT4 expression. It activated the IRS2/Akt/FoxO1 signaling axis, suppressed gluconeogenic gene expression, and improved hepatic lipid metabolism via modulation of SREBP-1c and PPARα/γ. In macrophages, LDR inhibited M1 polarization and pro-inflammatory cytokine production by reducing STAT3 activation, without affecting JAK2 expression. CETSA confirmed a direct interaction between LDR and STAT3 protein.Conclusion:Linderane ameliorates MASLD by targeting STAT3 to suppress hepatic inflammation and by activating IRS2–FoxO1 signaling to restore insulin sensitivity and metabolic homeostasis.These findings support Linderane as a promising natural agent that targets STAT3 and modulates metabolic pathways to alleviate MASLD.
- 23 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessLinderane, a furanosesquiterpene from Lindera aggregata, targets STAT3 to improve metabolic and inflammatory features of MASLD
Background:Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major global health burden, characterized by insulin resistance, hepatic steatosis, and chronic inflammation. Effective pharmacological treatments remain limited. Linderane (LDR), a furanosesquiterpene isolated from Lindera aggregata, exhibits immunometabolic regulatory activity; however, its role in MASLD has not been fully elucidated.Purpose:To evaluate the therapeutic potential of LDR in MASLD and explore its mechanisms, with a focus on STAT3-mediated immunometabolic pathways.Methods:MASLD was induced in C57BL/6J mice via high-fat diet (HFD) feeding. LDR was administered orally, and metabolic, inflammatory, and histological parameters were assessed. Mechanistic studies were performed in primary hepatocytes and macrophages using Western blotting, RT-qPCR, immunofluorescence, transcriptomics, and cellular thermal shift assays (CETSA).Results:LDR significantly improved fasting and postprandial glucose levels, enhanced insulin sensitivity, and restored GLUT2/GLUT4 expression. It activated the IRS2/Akt/FoxO1 signaling axis, suppressed gluconeogenic gene expression, and improved hepatic lipid metabolism via modulation of SREBP-1c and PPARα/γ. In macrophages, LDR inhibited M1 polarization and pro-inflammatory cytokine production by reducing STAT3 activation, without affecting JAK2 expression. CETSA confirmed a direct interaction between LDR and STAT3 protein.Conclusion:Linderane ameliorates MASLD by targeting STAT3 to suppress hepatic inflammation and by activating IRS2–FoxO1 signaling to restore insulin sensitivity and metabolic homeostasis.These findings support Linderane as a promising natural agent that targets STAT3 and modulates metabolic pathways to alleviate MASLD.
- 9 June 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 355 (Pt A) , 120101
Corrigendum to “Yinchen Gongying Decoction mitigates CCl4-induced chronic liver injury and fibrosis in mice implicated in inhibition of the FoxO1/TGF-β1/ Smad2/3 and YAP signaling pathways” [J. Ethnopharmacol. 327 (2024) 117975]
- 9 June 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 355 (Pt A) , 120101
Corrigendum to “Yinchen Gongying Decoction mitigates CCl4-induced chronic liver injury and fibrosis in mice implicated in inhibition of the FoxO1/TGF-β1/ Smad2/3 and YAP signaling pathways” [J. Ethnopharmacol. 327 (2024) 117975]
- 2 September 2024
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 15 (19) , 9863-9879
Effects of Mao tea from Nankun Mountain on nonalcoholic fatty liver disease in mice
Mao tea from Nankun Mountain alleviates NAFLD by inhibiting de novo lipid synthesis and the NF-κB pathway. The bioactive components group from MT plays the main role against NAFLD.
- 2 September 2024
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 15 (19) , 9863-9879
Effects of Mao tea from Nankun Mountain on nonalcoholic fatty liver disease in mice
Mao tea from Nankun Mountain alleviates NAFLD by inhibiting de novo lipid synthesis and the NF-κB pathway. The bioactive components group from MT plays the main role against NAFLD.
- Open Access
- 9 September 2023
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 17 (1) , 41-58
Hepatocyte FoxO1 Deficiency Protects From Liver Fibrosis via Reducing Inflammation and TGF-β1-mediated HSC Activation
- 9 September 2023
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 17 (1) , 41-58
Open AccessHepatocyte FoxO1 Deficiency Protects From Liver Fibrosis via Reducing Inflammation and TGF-β1-mediated HSC Activation